Portal de Periódicos da CAPES

Prognostic value of CD8CD45RO tumor infiltrating lymphocytes in patients with extrahepatic cholangiocarcinoma

2018; Impact Journals LLC; Volume: 9; Issue: 34 Linguagem: Inglês

10.18632/oncotarget.25163

1949-2553

Richard D. Kim, Domenico Coppola, Emilie Wang, Young D. Chang, Yuhree Kim, Daniel Anaya, Dae Won Kim,

Viral-associated cancers and disorders

// Richard Kim 1 , Domenico Coppola 2 , Emilie Wang 3 , Young Doo Chang 4 , Yuhree Kim 5 , Daniel Anaya 1 and Dae Won Kim 1 1 Department of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL, USA 2 Department of Anatomic Pathology, Moffitt Cancer Center, Tampa, FL, USA 3 Department of Internal Medicine, University of South Florida, Tampa, FL, USA 4 Department of Supportive Care, Moffitt Cancer Center, Tampa, FL, USA 5 Department of Population Medicine, Harvard Medical School, Boston, MA, USA Correspondence to: Richard Kim, email: richard.kim@moffitt.org Keywords: cholangiocarcinoma; tumor infiltrating lymphocytes; tumor microenvironment; PD-L1 Received: December 27, 2017 Accepted: April 02, 2018 Published: May 04, 2018 ABSTRACT Cholangiocarcinoma is a malignancy arising from the biliary tract epithelial cells with poor prognosis. Tumor infiltrating lymphocytes (TIL)s and programmed cell death receptor ligand 1 (PD-L1) have a prognostic impact in various solid tumors. We aimed to investigate TILs and PD-L1 expression and their clinical relevance in cholangiocarcinoma. Tumor samples from 44 patients with resected and histologically verified extrahepatic cholangiocarcinoma were evaluated for CD8, CD45RO and PD-L1 expression, and their correlations with clinicopathological data and survival data were analyzed. Total 44 extrahepatic cholangiocarcinoma tissues were evaluated. CD8+ tumor infiltrating lymphocytes (TIL)s were observed in 30 (68%) tumors. Among them, 14 had CD8+CD45RO+ TILs. PD-L1 was expressed on cancer cells in 10 (22.7%) tumors in 34 evaluable extrahepatic cholangiocarciniomas. The presence of CD8+ TILs or CD8+CD45RO+ TILs was not associated with clinical staging or tumor differentiation. Extrahepatic cholangiocarcinoma with CD8+CD45RO+ TILs had longer overall survival (OS) on univariate ( P = 0.013) and multivariate ( P = 0.012) analysis. Neither CD8+TIL nor PD-L1 expression on cancer cells correlated significantly with OS. These results add to the understanding of the clinical features associated with CD8 TILs and PD-L1 expression in extrahepatic cholangiocarcinoma, and they support the potential rationale of using PD-1 blockade immunotherapy in cholangiocarcinoma.